oral semaglutide vs oral tirzepatide tirzepatide: what actually exists, what does not, and what is coming next Lilly orforglipron oral GLP-1 phase – PDF) Indirect Comparative Efficacy and

The Golden Era of GLP-1 Drugs GLP-1 RAs are entero-pancreatic hormone-based treatments, first approved in 2005 for type 2 diabetes (T2D), and now commonly prescribed for weight loss and reduction of atherosclerotic cardiovascular (CV) risk in patients with T2D

With 19 approved therapies already on the market and an active clinical pipeline spanning hundreds of programs, the ADC sector has moved well past proof-of-concept and into a sustained commercial expansion Antibody Discovery Services and Platforms Market to Reach $6.3 Billion by 2035 a The global antibody discovery market, valued at $2.0 billion in 2025, will climb to $2.2 billion in 2026 and reach $6.3 billion by 2035, compounding at a CAGR of 12.3% over the forecast period

The additional GIP activation provides stronger effects on insulin sensitivity and glucose metabolism, which may be particularly relevant for Hashimoto's patients dealing with insulin resistance

Smart programming matters